Castle Biosciences (NASDAQ:CSTL) Given New $40.00 Price Target at KeyCorp

Posted by Stanley Muller on Nov 7th, 2026

Castle Biosciences (NASDAQ:CSTL – Free Report) had its price target upped by KeyCorp from $35.00 to $40.00 in a report issued on Friday,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

CSTL has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 29th. Robert W. Baird set a $36.00 price objective on Castle Biosciences in a research report on Friday, July 31st. Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. BTIG Research upped their target price on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Mizuho began coverage on Castle Biosciences in a research report on Thursday, October 29th. They issued an “outperform” rating and a $60.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Castle Biosciences currently has an average rating of “Moderate Buy” and an average price target of $44.88.

Get Our Latest Analysis on Castle Biosciences

Castle Biosciences Price Performance

Shares of Castle Biosciences stock traded down $1.68 during midday trading on Friday, hitting $32.52. 981,632 shares of the company traded hands, compared to its average volume of 352,839. The stock has a market cap of $993.49 million, a price-to-earnings ratio of -42.23 and a beta of 1.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. The firm’s fifty day moving average price is $34.25 and its 200-day moving average price is $28.53. Castle Biosciences has a 12 month low of $17.72 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.22. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The business had revenue of $101.95 million during the quarter, compared to the consensus estimate of $92.77 million. As a group, sell-side analysts forecast that Castle Biosciences will post -1.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Tobin W. Juvenal sold 9,050 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $35.04, for a total transaction of $317,112.00. Following the completion of the transaction, the insider directly owned 66,914 shares in the company, valued at $2,344,666.56. This trade represents a 11.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek Maetzold sold 12,428 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $33.20, for a total value of $412,609.60. Following the transaction, the insider owned 21,479 shares of the company’s stock, valued at $713,102.80. This trade represents a 36.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 126,184 shares of company stock valued at $4,324,506. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Castle Biosciences

Several institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co acquired a new position in shares of Castle Biosciences in the 3rd quarter worth approximately $339,000. Allworth Financial LP raised its stake in Castle Biosciences by 255.3% during the third quarter. Allworth Financial LP now owns 938 shares of the company’s stock worth $33,000 after buying an additional 674 shares during the last quarter. Pictet Asset Management Holding SA bought a new position in Castle Biosciences during the third quarter worth $210,000. Commonwealth Equity Services LLC acquired a new position in Castle Biosciences in the third quarter valued at $238,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Castle Biosciences in the third quarter valued at $55,000. 92.60% of the stock is currently owned by institutional investors.

Key Stories Impacting Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

Positive Sentiment: Q3 revenue rose 24% year over year to $102.9 million, beating analyst expectations, and the per-share loss of $0.13 was narrower than forecasts. Castle Biosciences Reports Third Quarter 2026 Results
Positive Sentiment: Management raised 2026 revenue guidance to $385–$395 million from $365–$375 million. TissueCypher test report volume increased 47% year over year, with the company signaling 50%–52% volume growth for the full year. Revenue outlook and TissueCypher growth
Positive Sentiment: KeyCorp raised its price target to $40 from $35 and maintained an Overweight rating, signaling potential upside in the firm’s view. KeyCorp recommendations
Negative Sentiment: The company remains unprofitable: its quarterly loss widened from $0.02 per share a year earlier to $0.13, despite beating analyst estimates. Ongoing losses could weigh on sentiment alongside the otherwise strong growth and guidance update. Q3 loss and revenue results

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.